Suppr超能文献

[嗜铬细胞瘤的治疗:诊断与治疗的变化]

[Treatment of pheochromocytoma: changes in diagnosis and therapy].

作者信息

Hauss J, Pircher W, Spiegel H U, Kertelge E, Roessner A, Vetter H

机构信息

Chirurgischen Klinik und Poliklinik, Gerhard-Domagk-Institut für Pathologie, Münster, BRD.

出版信息

Acta Med Austriaca. 1988;15(4):95-8.

PMID:3213383
Abstract

Evident progress has been made in the treatment of pheochromocytoma. The results of hormone analysis became very accurate, the method for tumor localisation are non invasive and safe: with 131-I-MIBG, ultrasonography and CT-scan an exact preoperative localisation is possible without serious risks. Patients are prepared for the operation with alpha- and beta-blocking agents. Modern methods of anaesthesia with continuous monitoring of blood pressure, pulmonary pressure and cardiac output and a standardized operative procedure are essential. From 1965 to 1987 71 patients with a total of 87 catecholamine producing tumors have been operated. In all cases a transabdominal access was chosen. Biadrenal tumors were removed in 8 patients, multiple (7) tumors in 2 patients. The comparison of the 2 time intervals 1965 to 1976 and 1977 to 1987 showed a significant decrease of serious intra- and postoperative complications. Surgical specimens of 36 patients with pheochromocytoma were used for immunohistologic evaluation. Marked positivity was found in 44% of cases for calcitonin. The reaction for vasoactive intestinal polypeptide (VIP) was positive in 28% of cases. Somatostatin was not detected in any case, neuron-specific enolase (NSE) in all cases. 6 patients with malignant pheochromocytoma were treated with high doses of 131-I-MIBG, 4 other patients received a combined chemotherapy.

摘要

嗜铬细胞瘤的治疗已取得明显进展。激素分析结果变得非常准确,肿瘤定位方法无创且安全:使用131-I-间碘苄胍、超声检查和CT扫描,术前可实现精确的定位且无严重风险。使用α和β阻滞剂让患者为手术做好准备。采用现代麻醉方法持续监测血压、肺动脉压和心输出量以及标准化的手术程序至关重要。1965年至1987年,共对71例患有87个产生儿茶酚胺肿瘤的患者进行了手术。所有病例均选择经腹入路。8例患者切除双侧肾上腺肿瘤,2例患者切除多个(7个)肿瘤。对1965年至1976年和1977年至1987年这两个时间段的比较显示,术中及术后严重并发症显著减少。36例嗜铬细胞瘤患者的手术标本用于免疫组织学评估。44%的病例降钙素呈明显阳性。28%的病例血管活性肠肽(VIP)反应呈阳性。所有病例均未检测到生长抑素,神经元特异性烯醇化酶(NSE)在所有病例中均有检测。6例恶性嗜铬细胞瘤患者接受了高剂量的131-I-间碘苄胍治疗,另外4例患者接受了联合化疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验